Page last updated: 2024-11-05

zardaverine and Lung Diseases, Obstructive

zardaverine has been researched along with Lung Diseases, Obstructive in 1 studies

zardaverine: structure given in first source
zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4.

Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.

Research Excerpts

ExcerptRelevanceReference
"Zardaverine is a selective inhibitor of phosphodiesterase (PDE) III and IV isozymes."2.68Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. ( Reiber, C; Rentz, K; Sybrecht, GW; Ukena, D, 1995)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ukena, D1
Rentz, K1
Reiber, C1
Sybrecht, GW1

Trials

1 trial available for zardaverine and Lung Diseases, Obstructive

ArticleYear
Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction.
    Respiratory medicine, 1995, Volume: 89, Issue:6

    Topics: Aged; Albuterol; Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Humans; Lung

1995